{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T10:29:27Z","timestamp":1782210567788,"version":"3.54.5"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T00:00:00Z","timestamp":1765584000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T00:00:00Z","timestamp":1765584000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Retin Vitr"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>In the early1990s, neovascular age-related macular degeneration (nAMD) was the leading cause of irreversible vision loss in older adults, yet its molecular basis remained unknown. In 1992, a hypothesis was proposed in which localized hypoxia could trigger vascular endothelial growth factor (VEGF)-mediated choroidal neovascularization in nAMD. Although hypoxia was recognized in ischemic retinopathies, nAMD was not considered a hypoxia-mediated retinal vascular disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Main body<\/jats:title>\n                    <jats:p>In 1994, this hypothesis was tested using antigen retrieval immunohistochemistry on paraffin-embedded whole human eye sections with early nAMD. The study demonstrated strong VEGF immunoreactivity in the retinal pigment epithelium in the macular area but not in normal control eyes, providing the first direct histopathologic evidence of VEGF expression at the site of disease in intact human eyes with early nAMD. Until that point, the role of VEGF in ischemic retinopathies was being uncovered, but its involvement in early-stage nAMD had not yet been demonstrated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The 1992\u20131994 work established both the hypothesis and the first direct tissue evidence linking VEGF to early nAMD. This discovery, made just over a decade before the advent of anti-VEGF therapy, anticipated one of ophthalmology\u2019s most transformative achievements, preserving vision for millions worldwide.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s40942-025-00779-x","type":"journal-article","created":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T05:55:03Z","timestamp":1765605303000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Histopathologic evidence of VEGF in early neovascular AMD: from a 1992 hypothesis to a 1994 discovery \u2014 a historical perspective"],"prefix":"10.1186","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-1426-9181","authenticated-orcid":false,"given":"K. Alexander","family":"Dastgheib","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,13]]},"reference":[{"issue":"15","key":"779_CR1","doi-asserted-by":"publisher","first-page":"1900","DOI":"10.1001\/jama.291.15.1900","volume":"291","author":"NM Bressler","year":"2004","unstructured":"Bressler NM. Age-related macular degeneration is the leading cause of blindness. JAMA. 2004;291(15):1900\u20131. https:\/\/doi.org\/10.1001\/jama.291.15.1900.","journal-title":"JAMA"},{"issue":"8","key":"779_CR2","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1001\/archopht.1991.01080080063023","volume":"109","author":"Macular Photocoagulation Study Group","year":"1991","unstructured":"Macular Photocoagulation Study Group. Argon laser photocoagulation for neovascular maculopathy. Five-year results from randomized clinical trials. Arch Ophthalmol. 1991;109(8):1109\u201314. https:\/\/doi.org\/10.1001\/archopht.1991.01080080063023.","journal-title":"Arch Ophthalmol"},{"key":"779_CR3","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1038\/eye.1990.86","volume":"4","author":"MC Killingsworth","year":"1990","unstructured":"Killingsworth MC, Sarks JP, Sarks SH. Macrophages related to bruch\u2019s membrane in age-related macular degeneration. Eye (Lond. 1990;4:613\u201321. https:\/\/doi.org\/10.1038\/eye.1990.86.","journal-title":"Eye (Lond"},{"issue":"2","key":"779_CR4","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/BF02150948","volume":"223","author":"PL Penfold","year":"1985","unstructured":"Penfold PL, Killingsworth MC, Sarks SH. Senile macular degeneration: the involvement of immunocompetent cells. Graefes Arch Clin Exp Ophthalmol. 1985;223(2):69\u201376. https:\/\/doi.org\/10.1007\/BF02150948.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"779_CR5","unstructured":"Penfold PL, Killingsworth MC, Sarks SH. Senile macular degeneration: the involvement of giant cells in atrophy of the retinal pigment epithelium. Invest Ophthalmol Vis Sci. 1986 Mar;27(3):364\u201371."},{"issue":"6","key":"779_CR6","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1001\/archopht.1994.01090180111045","volume":"112","author":"K Dastgheib","year":"1994","unstructured":"Dastgheib K, Green WR. Granulomatous reaction to bruch\u2019s membrane in age-related macular degeneration. Arch Ophthalmol. 1994;112(6):813\u20138. https:\/\/doi.org\/10.1001\/archopht.1994.01090180111045.","journal-title":"Arch Ophthalmol"},{"issue":"4935","key":"779_CR7","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1126\/science.2479986","volume":"246","author":"DW Leung","year":"1989","unstructured":"Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science. 1989;246(4935):1306\u20139. https:\/\/doi.org\/10.1126\/science.2479986.","journal-title":"Science"},{"issue":"4935","key":"779_CR8","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1126\/science.2479987","volume":"246","author":"PJ Keck","year":"1989","unstructured":"Keck PJ, Hauser SD, Krivi G, Sanzo K, Warren T, Feder J, Connolly DT. Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science. 1989;246(4935):1309\u201312. https:\/\/doi.org\/10.1126\/science.2479987.","journal-title":"Science"},{"issue":"6398","key":"779_CR9","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1038\/359843a0","volume":"359","author":"D Shweiki","year":"1992","unstructured":"Shweiki D, Itin A, Soffer D, Keshet E. Vascular endothelial growth factor induced by hypoxia May mediate hypoxia-initiated angiogenesis. Nature. 1992;359(6398):843\u20135. https:\/\/doi.org\/10.1038\/359843a0.","journal-title":"Nature"},{"key":"779_CR10","first-page":"332","volume-title":"Histology of the human eye","author":"MJ Hogan","year":"1971","unstructured":"Hogan MJ, Alvarado JA, Weddell JE. Histology of the human eye. Philadelphia, PA: WB Saunders; 1971. p. 332."},{"key":"779_CR11","unstructured":"Green WR. Age-related macular degeneration. In: Franklin RM, ed. Proceedings of the Symposium on Retina and Vitreous, New Orleans Academy of Ophthalmology; March 12\u201315, 1992; New Orleans, LA. Amsterdam\/New York: Kugler Publications;1993."},{"key":"779_CR12","first-page":"598","volume-title":"Ophthalmic pathology: an atlas and textbook","year":"1986","unstructured":"Spencer WH, editor. Ophthalmic pathology: an atlas and textbook. Volume 2, 3rd Vol ed. Philadelphia, PA: WB Saunders; 1986. p. 598.","edition":"3"},{"key":"779_CR13","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1177\/39.6.1709656","volume":"39","author":"SR Shi","year":"1991","unstructured":"Shi SR, Key ME, Kalra KI. Antigen retrieval in formalin-fixed, paraffin-embedded tissue: an enhancement method for immunohistochemical staining based on microwave oven heating of tissue sections. J Histochem Cytochem. 1991;39:741\u20138. https:\/\/doi.org\/10.1177\/39.6.1709656.","journal-title":"J Histochem Cytochem"},{"key":"779_CR14","unstructured":"Dastgheib K, Li Q, Chan C-C, Roberge FG, Csaky K, Green WR. Vascular endothelial growth factor (VEGF) in neovascular age-related macular degeneration. Wilmer Residents Association Meeting. Johns Hopkins University, Baltimore; April 1994."},{"issue":"4","key":"779_CR15","first-page":"S102","volume":"36","author":"K Dastgheib","year":"1995","unstructured":"Dastgheib K, Li Q, Chan C-C, Roberge FG, Csaky K, Green WR. Vascular endothelial growth factor (VEGF) in neovascular age-related macular degeneration. Invest Ophthalmol Vis Sci. 1995;36(4):S102.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"22","key":"779_CR16","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1056\/NEJM199412013312203","volume":"331","author":"LP Aiello","year":"1994","unstructured":"Aiello LP, Avery RL, Arrigg PG, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med. 1994;331(22):1480\u20137. https:\/\/doi.org\/10.1056\/NEJM199412013312203.","journal-title":"N Engl J Med"},{"issue":"3","key":"779_CR17","first-page":"574","volume":"145","author":"JW Miller","year":"1994","unstructured":"Miller JW, Adamis AP, Shima DT, et al. Vascular endothelial growth factor\/vascular permeability factor is temporally and spatially correlated with ocular angiogenesis in a primate model. Am J Pathol. 1994;145(3):574\u201384.","journal-title":"Am J Pathol"},{"issue":"1","key":"779_CR18","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1001\/archopht.1996.01100130062010","volume":"114","author":"AP Adamis","year":"1996","unstructured":"Adamis AP, Shima DT, Tolentino MJ, et al. Inhibition of vascular endothelial growth factor prevents retinal ischemia-associated Iris neovascularization in a nonhuman primate. Arch Ophthalmol. 1996;114(1):66\u201371. https:\/\/doi.org\/10.1001\/archopht.1996.01100130062010.","journal-title":"Arch Ophthalmol"},{"key":"779_CR19","doi-asserted-by":"publisher","first-page":"10457","DOI":"10.1073\/pnas.92.23.104","volume":"92","author":"LP Aiello","year":"1995","unstructured":"Aiello LP, Pierce EA, Foley ED, et al. Suppression of retinal neovascularization in vivo by Inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. Proc Natl Acad Sci USA. 1995;92:10457\u201361. https:\/\/doi.org\/10.1073\/pnas.92.23.104.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"6","key":"779_CR20","first-page":"615","volume":"72","author":"N Ferrara","year":"1995","unstructured":"Ferrara N. Vascular endothelial growth factor: the trigger for neovascularization in the eye. Lab Invest. 1995;72(6):615\u20138.","journal-title":"Lab Invest"},{"issue":"1","key":"779_CR21","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.ajo.2011.06.001","volume":"153","author":"R Dell\u2019Omo","year":"2012","unstructured":"Dell\u2019Omo R, Cassetta M, Dell\u2019Omo E, et al. Aqueous humor levels of vascular endothelial growth factor before and after intravitreal bevacizumab in type 3 versus type 1 and 2 neovascularization. A prospective, case-control study. Am J Ophthalmol. 2012;153(1):155\u201361. https:\/\/doi.org\/10.1016\/j.ajo.2011.06.001.","journal-title":"Am J Ophthalmol"},{"issue":"8","key":"779_CR22","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.ajo.2024.02.018","volume":"264","author":"HN Najeeb","year":"2024","unstructured":"Najeeb HN, Gerendas BS, Deak GG, et al. An automated comparative analysis of the exudative biomarkers in neovascular age-related macular degeneration, the RAP study: report 6. Am J Ophthalmol. 2024;264(8):53\u201365. https:\/\/doi.org\/10.1016\/j.ajo.2024.02.018.","journal-title":"Am J Ophthalmol"},{"key":"779_CR23","doi-asserted-by":"publisher","unstructured":"Miller JW. VEGF: from discovery to therapy: the Champalimaud award lecture. Translational Vis Sci Technol. 2016;5(2). https:\/\/doi.org\/10.1167\/tvst.5.2.9.","DOI":"10.1167\/tvst.5.2.9"},{"issue":"5","key":"779_CR24","first-page":"855","volume":"37","author":"PF Lopez","year":"1996","unstructured":"Lopez PF, Sippy BD, Lambert HM, et al. Transdifferentiated retinal pigment epithelial cells are immunoreactive for vascular endothelial growth factor in surgically excised age-related macular degeneration-related neovascular membranes. Invest Ophthalmol Vis Sci. 1996;37(5):855\u201368. PMID 8603870.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"9","key":"779_CR25","first-page":"1929","volume":"37","author":"A Kvanta","year":"1996","unstructured":"Kvanta A, Algvere PV, Berglin L, Seregard S. Subfoveal fibrovascular membranes in age-related macular degeneration express vascular endothelial growth factor. Invest Ophthalmol Vis Sci. 1996;37(9):1929\u201334. PMID 8759365.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"20","key":"779_CR26","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1056\/NEJMoa1102673","volume":"364","author":"DF Martin","year":"2011","unstructured":"Martin DF, Maguire MG, Ying GS, CATT Research Group, et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med. 2011;364(20):1897\u2013908. https:\/\/doi.org\/10.1056\/NEJMoa1102673.","journal-title":"N Engl J Med"},{"issue":"12","key":"779_CR27","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1016\/j.ophtha.2012.09.006","volume":"119","author":"JS Heier","year":"2012","unstructured":"Heier JS, Brown DM, Chong V, et al. VIEW 1 and VIEW 2 study Groups. Intravitreal Aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology. 2012;119(12):2537\u201348. https:\/\/doi.org\/10.1016\/j.ophtha.2012.09.006.","journal-title":"Ophthalmology"},{"key":"779_CR28","doi-asserted-by":"publisher","unstructured":"Gragoudas ES, Adamis AP, Cunningham ET Jr, Feinsod M, Guyer DR. VEGF Inhibition study in ocular neovascularization clinical trial group. pegaptanib for neovascular age-related macular degeneration. N Eng J Med. 20004;351:2805\u20132816. https:\/\/doi.org\/10.11056\/NEJMoa042760.","DOI":"10.11056\/NEJMoa042760"},{"issue":"3","key":"779_CR29","doi-asserted-by":"publisher","first-page":"CD005139","DOI":"10.1002\/14651858.CD005139.pub4","volume":"3","author":"SD Solomon","year":"2019","unstructured":"Solomon SD, Lindsley K, Vedula SS, et al. Anti-vascular endothelial growth factor for neovascular age-related macular degeneration. Cochrane Database Syst Rev. 2019;3(3):CD005139. https:\/\/doi.org\/10.1002\/14651858.CD005139.pub4.","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"779_CR30","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1186\/s12886-020-01554-2","volume":"20","author":"RP Finger","year":"2020","unstructured":"Finger RP, Daien V, Eldem BM, et al. Anti-vascular endothelial growth factor in neovascular age-related macular degeneration \u2013 a systematic review of the impact of anti-VEGF on patient outcomes and healthcare systems. BMC Ophthalmol. 2020;20(1):294. https:\/\/doi.org\/10.1186\/s12886-020-01554-2.","journal-title":"BMC Ophthalmol"},{"issue":"4","key":"779_CR31","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1016\/j.ophtha.2011.12.039","volume":"119","author":"QD Nguyen","year":"2012","unstructured":"Nguyen QD, Brown DM, Marcus DM, RISE and RIDE Research Group, et al. Ranibizumab for diabetic macular edema: results from phase III randomized trials: RISE and RIDE. Ophthalmology. 2012;119(4):789\u2013801. https:\/\/doi.org\/10.1016\/j.ophtha.2011.12.039.","journal-title":"Ophthalmology"},{"issue":"6","key":"779_CR32","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1016\/j.ophtha.2010.02.021","volume":"117","author":"PA Campochiaro","year":"2010","unstructured":"Campochiaro PA, Heier JS, Feiner L. BRAVO investigators. Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary endpoint results of a phase III study. Ophthalmology. 2010;117(6):1102\u2013e11121. https:\/\/doi.org\/10.1016\/j.ophtha.2010.02.021.","journal-title":"Ophthalmology"},{"issue":"6","key":"779_CR33","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1016\/j.ophtha.2010.02.022","volume":"117","author":"DM Brown","year":"2010","unstructured":"Brown DM, CampochiaroPA, Singh RP. CRUISE investigators. Ranibizumab for macular edema following central retinal vein occlusion: six-month primary endpoint results of a phase III study. Ophthalmology. 2010;117(6):1124\u2013e11331. https:\/\/doi.org\/10.1016\/j.ophtha.2010.02.022.","journal-title":"Ophthalmology"}],"container-title":["International Journal of Retina and Vitreous"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40942-025-00779-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40942-025-00779-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40942-025-00779-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T18:01:33Z","timestamp":1765648893000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40942-025-00779-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,13]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["779"],"URL":"https:\/\/doi.org\/10.1186\/s40942-025-00779-x","relation":{},"ISSN":["2056-9920"],"issn-type":[{"value":"2056-9920","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,13]]},"assertion":[{"value":"20 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. This study used archival, de-identified human ocular tissue specimens. No patient-identifiable information was included, and ethics approval therefore was not required. All procedures were conducted in accordance with the principles of the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"137"}}